Abstract
Tweetable abstract
The percentage of patients with immune-mediated vaccine-associated hepatitis is minimal compared with the number of patients vaccinated worldwide.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report. Immunotherapy 14(12), 915–925 (2022).
- 2. Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines. J. Hepatol. 77(5), 1339–1348 (2022).
- 3. . Autoimmune hepatitis-like syndrome following COVID-19 vaccination: a systematic review of the literature. Dig. Dis. Sci. 67(9), 4574–4580 (2022). • This paper illustrated how the approved vaccines trigger an autoimmune hepatitis-like syndrome.
- 4. Histological and serological features of acute liver injury after SARS-CoV-2 vaccination. JHEP Rep. 5(1), 100605 (2022). •• A very useful update on the current knowledge of histological features of acute liver injury after COVID-19 vaccines.
- 5. SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis. J. Hepatol. 77(3), 653–659 (2022).
- 6. . COVID-19 vaccination and liver disease. World J. Gastroenterol. 28(48), 6791–6810 (2022).
- 7. . Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front. Immunol. 11, 617089 (2021).
- 8. . CXCR3 enables recruitment and site-specific bystander activation of memory CD8+ T cells. Nat. Commun. 10(1), 4987 (2019).
- 9. . A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice. Blood 118(5), 1294–1304 (2011).
- 10. . COVID-19 vaccination can occasionally trigger autoimmune phenomena, probably via inducing age-associated B cells. Int. J. Rheum. Dis. 25(1), 83–85 (2022).
- 11. . Autoimmune hepatitis after COVID-19 vaccination. Front. Immunol. 13, 1035073 (2022).
- 12. . Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: unveiling the pathogenic, clinical and diagnostic aspects. J. Autoimmun. 47, 1–16 (2013).
- 13. . Could autoimmunity be induced by vaccination? Int. Rev. Immunol. 29(3), 247–269 (2010).
- 14. The “hit-and-run” strategy and the viral carcinogenesis. Future Oncol.
doi: 10.2217/fon-2022-1171 (2023) (Epub ahead of print). - 15. . Pathogens and autoimmune hepatitis. Clin. Exp. Immunol. 195(1), 35–51 (2019).
- 16. . Bystander activation and autoimmunity. J. Autoimmun. 103, 102301 (2019).
- 17. . The impact of antigenic molecular mimicry on anti-cancer T-cell immune response. Front. Oncol. 12, 1009247 (2022).
- 18. . Understanding immune responses to viruses–do underlying Th1/Th2 cell biases predict outcome? Viruses 14(7), 1493 (2022).
- 19. . Checkpoint inhibitor-induced hepatotoxicity: role of liver biopsy and management approach. World J. Hepatol. 14(7), 1269–1276 (2022).
- 20. Vaccine-related autoimmune hepatitis: emerging association with SARS-CoV-2 vaccination or coincidence? Vaccines (Basel) 10(12), 2073 (2022).